Rigel Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rigel Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Rigel Pharmaceuticals: 22 sponsored US clinical trials, 3 recruiting.
Rigel Pharmaceuticals sponsors 22 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 18 completed. 6 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Immune Thrombocytopenic Purpura, with 2 trials.
Top-decile sponsor footprint
Rigel Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
22 total, page 1 of 1
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07486713
Study of Olutasidenib and Temozolomide in HGG
NCT06161974
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
NCT05308264
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
NCT04904276
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
NCT04629703
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
NCT03764618
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
NCT02612558
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02076412
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
NCT02112838
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02077192
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02076399
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
NCT02040623
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
NCT01900249
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
NCT01733992
Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
NCT01597050
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
NCT01591044
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
NCT00798096
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
NCT00665626
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
NCT00665925
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
NCT00446095
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
NCT00706342
Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
NCT00326339
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Rigel Pharmaceuticals pipeline
3 recruiting of 22 indexed (14% open); 18 completed (82%).
Phase mix: 6 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Immune Thrombocytopenic Purpura (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rigel Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 22 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Rigel Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 trials (± recruiting share)
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Alexza Pharmaceuticals · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
Sponsors near 14% open enrollment (± trial volume)
- InMode MD · 14% recruiting · 22 trials
- Reproductive Medicine Associates of New Jersey · 14% recruiting · 51 trials
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Case Comprehensive Cancer Center · 14% recruiting · 407 trials
Related
What to do with this Rigel Pharmaceuticals page
22 registered trials is a research-attention snapshot, not an endorsement of Rigel Pharmaceuticals or any single study.
- 3 of Rigel Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Immune Thrombocytopenic Purpura is the condition Rigel Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Immune Thrombocytopenic Purpura trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rigel Pharmaceuticals pipeline card: 22 registered trials from official public datasets.Report a data error.